Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide and is frequently characterized by a hypoxic tumor microenvironment that facilitates tumor progression, cellular adaptation, and resistance to therapy. Emerging evidence implicates long non-coding RNAs (lncRNAs) as regulators of tumor-associated signaling networks. The role of the lncRNA MIR100HG in HCC, and specifically how its effects vary with cellular oxygenation, was incompletely understood prior to the study summarized here.
The investigation assessed MIR100HG expression and function using two hepatocellular carcinoma cell lines with distinct phenotypes—epithelial-like Hep3B and mesenchymal-like SNU-398—together with a non-tumor hepatocyte line (Clone-9). The authors applied gain- and loss-of-function strategies (MIR100HG overexpression and silencing) to probe consequences for tumor-associated cellular behaviors. Functional assays measured cell proliferation, clonogenic potential, migration, invasion, and apoptotic cell death under both normoxic and hypoxia-mimicking conditions. Pathway-level analyses focused on phosphorylation status of signaling proteins and expression of AKT-associated regulatory genes.
Manipulating MIR100HG levels produced consistent changes in cellular phenotypes relevant to tumorigenesis. Overexpression of MIR100HG markedly enhanced proliferation, colony formation, migration, and invasion in the HCC cell models. Conversely, silencing MIR100HG reduced these tumorigenic properties and increased apoptotic cell death. These data indicate that MIR100HG functions as an oncogenic regulator of multiple malignant phenotypes in vitro.
Mechanistic analyses performed under normoxic conditions showed that MIR100HG promotes oncogenic signaling through activation of the p38/MAPK and AKT pathways. Specifically, MIR100HG expression was associated with increased phosphorylation of these key signaling proteins, while MIR100HG depletion reduced their phosphorylation. These findings link the tumor-promoting phenotypes driven by MIR100HG to enhanced survival and proliferative signaling mediated by p38/MAPK and AKT under normoxia.
When cells were exposed to hypoxia-mimicking conditions, the signaling consequences of MIR100HG expression diverged from those seen in normoxia. The study reports that the MIR100HG-associated activation of p38/MAPK and AKT observed in normoxic cells was not maintained under hypoxia-mimicking conditions. This indicates that the downstream signaling network engaged by MIR100HG is highly dependent on cellular oxygenation and that hypoxia reshapes how MIR100HG influences pathway activation.
Further pathway analyses revealed that expression patterns of AKT-associated regulatory genes, including GAS6 and PTEN, were reversed under hypoxia-mimicking conditions compared with normoxia. The reversal of these regulatory gene expression profiles provides additional evidence that hypoxia alters the regulatory landscape downstream of MIR100HG, potentially changing the balance of pro-survival and tumor-suppressive influences on AKT signaling.
Collectively, the results identify MIR100HG as a hypoxia-associated oncogenic regulator that enhances tumorigenic phenotypes and promotes survival signaling in HCC cell models. The context-dependent nature of MIR100HG effects—strong activation of p38/MAPK and AKT under normoxia but altered signaling under hypoxia—highlights the importance of tumor oxygenation when considering MIR100HG as a biomarker or therapeutic target. The findings support further investigation of MIR100HG in HCC, including whether MIR100HG expression correlates with hypoxic signatures, clinical outcomes, or responses to targeted therapies in patient-derived samples or in vivo models.
The abstract reports in vitro observations in specific HCC cell lines and non-tumor hepatocytes; details on in vivo validation, clinical correlation, or patient sample analysis were not provided in the source abstract. The authors declared no competing interests and stated that ethical approval was not required because no animal or human subjects were used. Future work should clarify whether the oxygen-dependent signaling behaviors of MIR100HG translate to tumor tissues and whether targeting MIR100HG affects tumor growth or therapeutic sensitivity in vivo.